Search Result

Results for "

benign prostatic hyperplasia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (10) Adrenergic Receptor (31) Androgen Receptor (4) Apoptosis (2) Bacterial (2) Biochemical Assay Reagents (1) Drug Derivative (1) Endogenous Metabolite (2) Environmental Pollutants (1) G protein-coupled Bile Acid Receptor 1 (1) Isotope-Labeled Compounds (7) LPL Receptor (1) Phosphodiesterase (PDE) (2) Pyruvate Kinase (1) Reference Standards (10) Serotonin Transporter (4)
By Research Areas:	Cancer (16) Cardiovascular Disease (7) Endocrinology (29) Infection (1) Inflammation/Immunology (2) Metabolic Disease (12) Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13635

Finasteride 4 Publications Verification MK-906	Environmental Pollutants 5 alpha Reductase	Cancer
Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-B0371F

Terazosin hydrochloride Maximum Cited Publications 7 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-10122

Silodosin 5 Publications Verification KAD 3213; KMD 3213	Adrenergic Receptor Bacterial	Endocrinology Cancer
Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (K_i=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .

HY-B0304A

Dapoxetine hydrochloride 1 Publications Verification LY-210448 hydrochloride	Serotonin Transporter	Neurological Disease
Dapoxetine (LY-210448) hydrochloride is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine hydrochloride can be used for the research of premature ejaculation (PE) .

HY-B0192

Alfuzosin 1 Publications Verification SL 77499	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0371

Terazosin 5+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371A

Terazosin hydrochloride dihydrate Maximum Cited Publications 7 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0192A

Alfuzosin hydrochloride 1 Publications Verification SL 77499-10	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-P3501

Fexapotide NX-1207	Apoptosis	Cancer
Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-158498

FA2 glycan (G0F) FA2 N-linked oligosaccharide; F(6)A2 glycan	Biochemical Assay Reagents	Cancer
FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research .

HY-103204

RS100329 hydrochloride	Adrenergic Receptor	Endocrinology
RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pK_i values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .

HY-N8850

Angelol G	Others	Cancer
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-B0304

Dapoxetine (S)-(+)-Dapoxetine; LY-210448	Serotonin Transporter	Neurological Disease
Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE) .

HY-13635A

Finasteride acetate MK-906 acetate	5 alpha Reductase	Cancer
Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-12718

(±)-WB 4101	Adrenergic Receptor	Cardiovascular Disease
(±)-WB 4101 is a highly selective α1-adrenergic receptor antagonist. (±)-WB 4101 blocks norepinephrine-induced vascular smooth muscle contraction to exert antihypertensive and benign prostatic hyperplasia (BPH)-relieving effects. (±)-WB 4101 is promising for research of hypertension and BPH .

HY-B0371S

Terazosin-d8	Isotope-Labeled Compounds Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-13635R

Finasteride (Standard) MK-906 (Standard)	Reference Standards 5 alpha Reductase	Cancer
Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-106614

Osaterone acetate	Androgen Receptor 5 alpha Reductase	Endocrinology
Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs .

HY-165478

FCE 28260	5 alpha Reductase	Endocrinology
FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH) .

HY-19144

ONO-3805	5 alpha Reductase	Others
ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.

HY-134632

Dehydro silodosin KMD-3241	Adrenergic Receptor	Cancer
Dehydro silodosin (KMD-3241) is a selective α1A-adrenoceptor antagonist used in the study of benign prostatic hyperplasia .

HY-103202

SNAP5089 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
SNAP5089 (hydrochloride) is a selective α1A adrenergic receptor antagonist. SNAP5089 (hydrochloride) can be used in the research of hypertension and benign prostatic hyperplasia .

HY-106363

MK-0963 L 654066	5 alpha Reductase	Others
MK-0963 is a steroidal 5α-reductase inhibitor. MK-0963 reduces serum dihydrotestosterone (DHT) concentrations in a dose-dependent manner. MK-0963 can be used for the study of dihydrotestosterone-related diseases such as benign prostate hyperplasia (BPH) .

HY-B0192AR

Alfuzosin hydrochloride (Standard) SL 77499-10 (Standard)	Reference Standards Adrenergic Receptor	Endocrinology
Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-123323

MK-0434	5 alpha Reductase	Endocrinology
MK-0434 is an orally active steroid 5α-reductase inhibitor. MK-0434 specifically inhibits steroid 5α-reductase, thereby reducing the level of dihydrotestosterone (DHT) in the body. MK-0434 can be used in the study of benign prostatic hyperplasia .

HY-101826A

ER21355 hydrochloride	Phosphodiesterase (PDE)	Cancer
ER21355 hydrochloride is the hydrochloride form of ER21355 (HY-101826). ER21355 hydrochloride is an inhibitor for phosphodiesterase (PDE), which is potent for ameliorating benign prostatic hyperplasia (BPH) and prostatism through increasing levels of cAMP and cGMP, and resulting a relaxation of the smooth muscle cell .

HY-P3501A

Fexapotide TFA NX-1207 TFA	Apoptosis	Cancer
Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-19268

GG-818 GW 1818	Adrenergic Receptor	Metabolic Disease
GG-818 (GW 1818) is a potent and selective α1 adrenoceptor antagonist, with pK_i values of 9.7 for α1_a, 7.8 for α1_b, and 7.6 for α1_d. GG-818 (GW 1818) can be used for benign prostatic hyperplasia research .

HY-17019

SL-89.0591	Adrenergic Receptor	Inflammation/Immunology
SL-89.0591 is a uroselective α1-adrenoceptor antagonist. SL-89.0591 exhibits a more potent blocking effect on urethral receptors than on vascular receptors in anesthetized rabbits, with a lower risk of orthostatic hypotension. SL-89.0591 can be used in research related to benign prostatic hyperplasia .

HY-116379

RS-100329	Adrenergic Receptor	Metabolic Disease
RS-100329 is an α1-adrenergic receptor (α1-AR) antagonist that effectively inhibits α1-adrenergic receptor-mediated contractions of lower urinary tract tissues in vitro and in vivo. RS-100329 can be used in the research of symptoms related to benign prostatic hyperplasia .

HY-135473

Chlormadinone	Androgen Receptor	Metabolic Disease Endocrinology Cancer
Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-B0371FR

Terazosin hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin (hydrochloride) (Standard) is the analytical standard of Terazosin (hydrochloride). This product is intended for research and analytical applications. Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371AR

Terazosin hydrochloride dihydrate (Standard)	Reference Standards Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin (hydrochloride dihydrate) (Standard) is the analytical standard of Terazosin (hydrochloride dihydrate). This product is intended for research and analytical applications. Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-135473S

Chlormadinone-d6	Isotope-Labeled Compounds Androgen Receptor	Metabolic Disease
Chlormadinone-d₆ is the deuterium labeled Chlormadinone (HY-135473). Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-135473R

Chlormadinone (Standard)	Androgen Receptor Reference Standards	Metabolic Disease
Chlormadinone (Standard) is the analytical standard of Chlormadinone (HY-135473). This product is intended for research and analytical applications. Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-W724254

SNAP-6201	Adrenergic Receptor	Endocrinology
SNAP-6201 is a selective α_1a adrenoceptor antagonist with a K_i of 0.2 nM. SNAP-6201 exhibits >1400-fold selectivity over α_1b and α_1d adrenoceptors. SNAP-6201 exhibits excellent selectively to inhibit intraurethral pressure (IUP) in the anesthetized dog model. SNAP-6201 can be used for benign prostatic hyperplasia (BPH) research .

HY-B0192AS

Alfuzosin-d3 hydrochloride SL 77499-10-d₃	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192AS1

Alfuzosin-d7 hydrochloride SL 77499-10-d₇	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-123710

GYKI-16084	Endogenous Metabolite	Others
GYKI-16084 is a new compound that can be isolated from dog and rat urine. GYKI-16084 can be used in the research of benign prostatic hyperplasia .

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

HY-Z12431

Silodosin carboxylic acid impurity KMD-3293	Endogenous Metabolite	Metabolic Disease
Silodosin carboxylic acid impurity (KMD-3293) is an inactive silodosin metabolite. Silodosin carboxylic acid impurity is the major metabolite that can be generated via oxidation by alcohol and aldehyde dehydrogenase. Silodosin carboxylic acid impurity can be studied in research for benign prostatic hyperplasia .

HY-B0192S

Alfuzosin-d7 SL 77499-d₇	Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ is the deuterium labeled Alfuzosin . Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192R

Alfuzosin (Standard) SL 77499 (Standard)	Adrenergic Receptor Reference Standards	Endocrinology
Alfuzosin (Standard) is the analytical standard of Alfuzosin. This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192S3

Alfuzosin-d6 SL 77499-d₆	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d₆ (SL 77499-d₆) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192S3A

Alfuzosin hydrochloride-d6 SL 77499-10-d₆	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin (hydrochloride)-d₆ (SL 77499-10-d₆) is deuterium labeled Alfuzosin (hydrochloride). Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-13635S

Finasteride-d9 MK-906-d₉	Isotope-Labeled Compounds 5 alpha Reductase	Cancer
Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-W357141

Methyl 2-O-β-D-glucopyranosylbenzoate Methyl salicylate 2-O-β-D-glucopyranoside	Drug Derivative	Inflammation/Immunology
Methyl 2-O-β-D-glucopyranosylbenzoate (Methyl salicylate 2-O-β-D-glucopyranoside) (Compound 11) is a phenolic compound. Methyl 2-O-β-D-glucopyranosylbenzoate can be isolated from the leaves of Metapanax delavayi. Methyl 2-O-β-D-glucopyranosylbenzoate has anti-benign prostatic hyperplasia activities and significantly inhibits the proliferation of BPH-1 cells. β-Phenylethyl β-D-glucoside can be used for prostatitis research .

HY-162071

PKM2-IN-5	Pyruvate Kinase	Cancer
PKM2-IN-5 (Compound G1) is an inhibitor for pyruvate kinase M2 (PKM2), with IC₅₀ >70 μM .

HY-10122R

Silodosin (Standard) KAD 3213 (Standard); KMD 3213 (Standard)	Reference Standards Adrenergic Receptor Bacterial	Endocrinology Cancer
Silodosin (Standard) is the analytical standard of Silodosin. This product is intended for research and analytical applications. Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (K_i=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .

Cat. No.	Product Name	Type

HY-158498

FA2 glycan (G0F)

FA2 N-linked oligosaccharide; F(6)A2 glycan

Biochemical Assay Reagents

FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P3501

Fexapotide NX-1207	Apoptosis	Cancer
Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-P3501A

Fexapotide TFA NX-1207 TFA	Apoptosis	Cancer
Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0371

Terazosin 5+ Cited Publications	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-N8850

Angelol G	Leguminosae Campylotropis hirtella (Franch.) Schindl. Coumarins Phenylpropanoids Plants Source Classification	Others
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-W357141

Methyl 2-O-β-D-glucopyranosylbenzoate Methyl salicylate 2-O-β-D-glucopyranoside	Structural Classification Piperaceae Piper crocatum Ruiz & Pav. Plants Saccharides Monosaccharides Source Classification	Drug Derivative
Methyl 2-O-β-D-glucopyranosylbenzoate (Methyl salicylate 2-O-β-D-glucopyranoside) (Compound 11) is a phenolic compound. Methyl 2-O-β-D-glucopyranosylbenzoate can be isolated from the leaves of Metapanax delavayi. Methyl 2-O-β-D-glucopyranosylbenzoate has anti-benign prostatic hyperplasia activities and significantly inhibits the proliferation of BPH-1 cells. β-Phenylethyl β-D-glucoside can be used for prostatitis research .

HY-N13195

(15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one	Triterpenes Microorganisms Terpenoids Source Classification	5 alpha Reductase
(15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one shows a 5a-reductase inhibitory activity with an IC₅₀ value of 41.9 μM. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one inhibits the growth of the ventral prostate induced by testosterone in rat. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is promising for research of benign prostatic hyperplasia (BPH) as well as other 5α-dihydrotestosterone (DHT)-related disorders, such as acne and male pattern baldness .

HY-N18683

Saw palmetto extract	Structural Classification Extract	Others
Saw palmetto extract can be used to study lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).

Cat. No.	Product Name	Chemical Structure

HY-B0371S

Terazosin-d8
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-135473S

Chlormadinone-d6
Chlormadinone-d₆ is the deuterium labeled Chlormadinone (HY-135473). Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-B0192AS

Alfuzosin-d3 hydrochloride
Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192AS1

Alfuzosin-d7 hydrochloride
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192S

Alfuzosin-d7
Alfuzosin-d₇ is the deuterium labeled Alfuzosin . Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192S3

Alfuzosin-d6
Alfuzosin-d₆ (SL 77499-d₆) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192S3A

Alfuzosin hydrochloride-d6

Alfuzosin (hydrochloride)-d₆ (SL 77499-10-d₆) is deuterium labeled Alfuzosin (hydrochloride). Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-13635S

Finasteride-d9

Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

benign prostatic hyperplasia

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products